Global Antibody Fragments Market Size study & Forecast, by Product (FAB, scFv, sdAb, Others), by Application (Cancer, Immunodeficiency, Others) and Regional Analysis, 2022-2029

Global Antibody Fragments Market Size study & Forecast, by Product (FAB, scFv, sdAb, Others), by Application (Cancer, Immunodeficiency, Others) and Regional Analysis, 2022-2029

Global Antibody Fragments Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Antibody fragments are the smallest part of an antibody that is obtained after the papain or pepsin digestion of full-length antibodies. Antibodies work by targeting specific antigens, cells, or molecules in order to perform various functions such as improving immune response against malignancies or infections and serving as “traffic signals” for white blood cells. Factors such as the increase in chronic conditions such as cancer, immunodeficiency, and others, increasing expenditure on healthcare activities, coupled with the introduction of advanced recombinant DNA technology for diagnosis and therapeutics are the primary factors that are propelling the market demand worldwide.

According to National Cancer Institute, in 2018, the number of cancer patients is recorded with 18.1 million cases, which is anticipated to increase to 29.5 million cases by the year 2040. Thereby, the increasing incidences of cancer and other chronic conditions are propelling the demand for Antibody Fragments, which is augmenting the market growth in the near future. In addition, growing investment in R&D activities and the rising number of clinical developments for antibody fragments and related products for serious diseases are the factors that are providing lucrative opportunities for global market growth. However, obstacles associated with the purification of antibody fragments and the imposition of stringent regulatory norms for the approval of antibody fragments hamper market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Antibody Fragments Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the space in terms of revenue, owing to the growth of regional pharmaceutical industries, availability of R&D funding, and increasing market players across the world. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as increasing focus on the biologics manufacturing sector, rising immunodeficiency diseases and cancer, along with the escalating population.

Major market players included in this report are:
Pfizer Inc.
Albynx
Novartis AG
Genentech, Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Private Limited
Lilly
Takeda Pharmaceutical Company Limited
Sanofi

Recent Developments in the Market:

In March 2021, Amgen Inc. declared the acquisition of Rodeo Therapeutics- a biopharmaceutical company, for USD 720 million. The aim of this acquisition is to develop small-molecule therapies for regeneration and repair of multiple tissues.

In March 2021, Amgen Inc. unveils the acquisition of Five Prime Therapeutics, and its lead candidate, bemarituzumab, for gastric cancer, with around USD 1.9 billion. The objective of this acquisition is to enhance the scope of targeted cancer therapies and immuno-oncology.
Global Antibody Fragments Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage
Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered
Product, Application, Region
Regional Scope
North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope
Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below.
By Product:
FAB
scFv
sdAb
Others
By Application:
Cancer
Immunodeficiency
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australi.
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Pfizer Inc.
Albynx
Novartis AG
Genentech, Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Private Limited
Lilly
Takeda Pharmaceutical Company Limited
Sanofi

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.